Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.


Professor of Cardiology. Vita Salute University and San Raffaele Hospital, Milan, Italy
Paolo G. Camici is Professor of Cardiology at the Vita-Salute University San Raffaele and a Senior Consultant in Cardiology in the Department of Cardiovascular Medicine at San Raffaele Hospital in Milan, Italy. Up to April 2010 he was Professor of Cardiovascular Pathophysiology and Consultant Cardiologist at Hammersmith Hospital in London, which is part of Imperial College School of Medicine. There, he was also director of the cardiac PET Program at the MRC Clinical Sciences Centre.

Professor’s Camici practice specializes in the diagnosis and treatment of ischemic heart disease and cardiomyopathies. His research has contributed to the characterization of a novel condition known as coronary microvascular dysfunction, which affects the small vessels of the heart. Professor Camici is also an expert in the treatment of post-ischemic left ventricular dysfunction and heart failure. In addition, he is a recognized international expert in noninvasive cardiac imaging, particularly PET.

He is a Fellow of the American Heart Association, the American College of Cardiology, the European Society of Cardiology, the American Heart Association, and the Royal College of Physicians.

Since September 2016, He is Editor in Chief of the International Journal of Cardiology.


He has received research grants from the British Heart Foundation, the Medical Research Council, the Wellcome Trust, and the Italian Ministry of Health, and from pharmaceutical companies, including Servier, Novartis, Menarini and Gilead.